tirzepatide by lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry Eli Lilly: Tirzepatide Single-Dose Vials

Lilly: Weight-loss drug resolves sleep apnea in up to 52% of patients Eli Lilly today said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials

For those without insurance, affordable self-pay options are also available

Target 0.7 to 1.0 grams of protein per pound of goal body weight daily

any dosing figures describe clinical-trial or research settings, not a personal protocol

Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study

Through Gifthealths relationship with LillyDirect, we provide a seamless, affordable path for patients to receive this FDA-approved treatment